Announcements

Job offersmore »

Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




US: Broad files update to CRISPR-Cas9 portfolio

The Rockefeller University and the Broad Institute of MIT and Harvard have settled their disagreement regarding inventorship and ownership of certain Broad filings relating to the use of the CRISPR-Cas9 system in eukaryotic cells. Rockefeller believed that its faculty member Dr. Luciano Marraffini, co-author with Broad’s Dr. Feng Zhang, on a seminal paper published in Science in 2013, Multiplex Genome Engineering Using CRISPR/Cas Systems, should have been maintained in these Broad eukaryote filings.

The parties agreed to submit their dispute to binding arbitration, in which it was decided that inventorship on Broad’s eukaryote filings in US Patent 8,697,359, and Patent Cooperation Treaty (PCT) applications PCT/US2013/074667, PCT/US2013/074691, PCT/US2013/074736, PCT/US2013/074743, PCT/US2013/074812, PCT/US2013/074819, PCT/US2013/074825, PCT/US2013/074790 or PCT/US2013/074800; or US application 15/349,603 will remain unchanged. The Broad Institute manages a robust CRISPR-Cas9 patent portfolio including key CRISPR-Cas9 patents in the United States and Europe relating to use of CRISPR-Cas9 in eukaryotic cells.

In addition, the Broad Institute portfolio includes filings relating to the use of the CRISPR-Cas9 system in prokaryotic cells, on which Drs. Marraffini and Zhang are co-inventors and Rockefeller and Broad are joint owners.

The Broad Institute and Rockefeller make CRISPR tools freely available to the academic and nonprofit communities and issue non-exclusive licenses for most types of commercial research. In July, 2017, the institutions joined discussions to create a worldwide CRISPR-Cas9 licensing pool. For human therapeutics, the Broad Institute places limits on exclusivity through its Inclusive Innovation model, which offers one licensee exclusive use for a defined period (two years), followed by an open call for applications by other groups. In the case of CRISPR-Cas9, the two-year exclusive period has already ended. Parties interested in licensing the technology are invited to apply through the Broad website.

Publication date: 1/16/2018

 


 

Other news in this sector:

8/17/2018 Canada invests in vegetable breeding research
8/16/2018 "Gene-editing startups ignite the next 'Frankenfood' fight"
8/15/2018 Next stage for Advanced Berry Breeding
8/14/2018 Inari secures $40 million to expand plant breeding technologies
8/13/2018 More hot peppers grown in Argentina in recent years
8/13/2018 Proteins generate 'wow factors' in fruits and vegetables
8/10/2018 US (NM): Inside the world’s only chile pepper research institute
8/9/2018 GMO eggplant crop expands in Bangladesh
8/9/2018 The art of the multilateral deal
8/9/2018 Video: Collecting crop wild relatives
8/9/2018 Brazil: A cherry tomato with more sugar and lycopene
8/8/2018 Seed production in Tasmania
8/7/2018 Baby bell pepper gets new colour
8/7/2018 ‘Weird, new fruits soon to hit shelves’
8/6/2018 “CRISPR Cas and other new plant breeding techniques are GMO”
7/20/2018 Syngenta lettuce varieties, resistant to the new Bremia races BI: 34-35
7/20/2018 Plant breeder shares profits with growers in developing countries
7/20/2018 New company seeks to shake up plant breeding
7/20/2018 New Zealand: Retired researcher breeds out-of-season strawberries
7/19/2018 Ukraine: Tomato Field Day in Kamenka